The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
The protocol involves using CRISPR-Cas9 gene editing to knock out the NRF2 gene in KRAS-positive NSCLC patients who have become resistant to chemotherapy.
Researchers used a genome-scale CRISPRi platform to identify genetic interactions with an inhibitor for a mutant form of KRAS in models of lung and pancreatic cancer.
The researchers created a resource of cancer dependencies and developed a framework to prioritize existing cancer drug targets and suggest new ones.
Centene will contribute up to $100 million over 10 years to fund research into Alzheimer's disease, breast cancer, diabetes, and obesity at WashU.
The researchers said their findings could help classify BRCA1 variants, particularly one whose impact on cancer risk is currently not clear.